Buzz: Baxter is considering selling its vaccine unit

Baxter announced Thursday morning it will split into two companies, separating its $6 billion biopharma operation from its $9 billion medical device and diagnostics business. The company is also looking into selling its vaccine business, Reuters reported Wednesday. The process is at an early stage, with Baxter having recently tapped Goldman Sachs to advise and begun contacting potential buyers, including private equity firms. Sales of vaccines against meningitis C and tick-borne encephalitis helped the business bring in $300 million last year. The unit is profitable, but Baxter reportedly considers it noncore. Novartis ($NVS) is also thinking of selling its vaccine unit. Article | More from FierceBiotech

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.